KyungDong Pharm home
Prescription Medicines

Atenol Tab.

Product Category
β1-receptor blockers
Active Ingredients
Atenolol
Appearance
White round film-coated tablet
Reimbursement Code
648101420
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength : 1 tablet
- Active ingredient: Atenolol (USP) ---------- 50mg
- Additives: Microcrystalline cellulose, titanium oxide, magnesium stearate, silicon dioxide, sodium starch glycolate, polyethylene glycol 6000, hypromellose 2910

2. Efficacy/Effectiveness
high blood pressure, angina pectoris

3. Usage/Dosage
1. High blood pressure: Adult initial dose is atenolol, 50 mg once a day, administered orally alone or in combination with a diuretic (thiazide), if the effect is not apparent within 1-2 weeks.
Increase the dose to 100 mg once a day. Do not exceed more than 100 mg per day.
2. Angina: Administer 100 mg of this drug 1-2 times per day in divided doses and do not exceed 100 mg per day.
3. Patients with renal impairment
※ Please check the attached document for details.
Increase or decrease appropriately depending on age and symptoms.

4. Precautions for use
1. Do not administer to the following patients.
1) Patients with hypersensitivity to the main ingredients or excipients of this drug
2) Patients with severe bronchial asthma or chronic obstructive pulmonary disease
3) Patients with diabetic ketoacidosis and metabolic acidosis
4) Patients with bradycardia (marked sinus bradycardia below 45bpm), atrioventricular block (2nd, 3rd degree), sinoatrial block
5) Patients with psychogenic shock
6) Patients with right heart failure due to pulmonary hypertension
7) Patients with congestive heart failure
8) Patients with severe low blood pressure
9) Patients with severe peripheral circulation disorders
10) Patients with motor dysfunction syndrome
11) Patients who may develop thyrotoxicosis due to this drug
12) Untreated pheochromocytoma patient

2. Administer with caution to the following patients.
1) Patients who may develop bronchial asthma or bronchospasm (administer cautiously, including sufficient observation and concurrent use of bronchodilators)
2) Patients who may develop congestive heart failure (observe sufficiently and administer cautiously, such as in combination with digitalis preparations)
3) Patients with idiopathic hypoglycemia, poorly controlled diabetes, and long-term fasting (be careful of blood sugar levels as symptoms of hypoglycemia can easily occur and symptoms can easily be hidden.)
4) Patients with severe liver and kidney disorders
5) Patients with pheochromocytoma (administer α-blocker in combination)
6) Elderly (start administration at low dose)

3. Adverse reactions
1) Hypersensitivity: Occasionally rash, itching, etc. may occur, so in such cases, discontinue administration. Additionally, hypersensitivity reactions such as angioedema or hives may occur.
2) Eyes: There have been reports of decreased tear secretion when administering β-blockers, so in such cases, discontinue administration. Additionally, visual impairment such as blurred vision and dry eyes may occur.
3) Circulatory system: Commonly, bradycardia, cold hands and feet, sometimes palpitations, cardiothoracic hypertrophy, chest pressure, hypotension, cold extremities, atrioventricular block, rarely sinoatrial block, orthostatic hypotension, leg pain, heart failure, etc. may occur. In susceptible patients, accelerated heart block, intermittent claudication, and Raynaud's phenomenon may occur.
4) Mental nervous system: Confusion, mood changes, nightmares, insanity and hallucinations, sleep disorders of the type reported with other β-blockers, sometimes heaviness, dizziness, orthostatic control disorder, insomnia, drowsiness, and rarely, congestion, ringing, tinnitus, ear pain, fatigue, helplessness, malaise, headache, paresthesia, and impaired consciousness.
5) Digestive system: Gastrointestinal disorders, rarely dry mouth, nausea, vomiting, loss of appetite, abdominal discomfort, diarrhea, loose stools, constipation, abdominal pain, etc. may occur.
6) Respiratory system, chest and mediastinum: In rare cases, wheezing, difficulty breathing, and bronchospasm may occur. Rarely, bronchospasm may occur in patients with bronchial asthma or a history of asthma.
7) Liver: Occasionally, elevations of AST and ALT may occur, and in rare cases, hepatotoxicity including intrahepatic cholestasis has been reported.
8) Kidney: Rarely, increases in BUN and creatinine may occur.
9) Skin and subcutaneous skin: Rash, psoriasis or psoriatic rash, and alopecia may appear. In rare cases, hives may appear.
10) Blood and lymph: purpura, thrombocytopenia
11) Reproduction: Erectile dysfunction
12) Others: Sometimes numbness, swelling/peripheral edema, rarely sweating, feeling cold, frequent urination, and increased transaminase levels may occur. Additionally, hyperlipidemia, hyperglycemia, hyperuricemia, and elevation of CPK may occasionally occur. An increase in antinuclear antibodies has been observed, but the clinical correlation is not clear.
13) The following adverse reactions have been reported with β-blockers.
① Blood: Agranulocytosis, non-thrombocytopenic purpura, thrombocytopenic purpura
② Allergy: Tonsillitis, laryngospasm, breathing disorder
③ Central nervous system: Reversible depression causing liver disease, reversible acute symptoms due to visual impairment, hallucinations, and disorientation, short-term memory loss, emotional instability due to mild sensory confusion, and reduction of neuropsychiatric behavior.
④ Digestive system: mesenteric artery thrombosis, ischemic colitis
⑤ Others: Reversible hair loss, Peyronie's disease, erythematous rash, Raynaud's phenomenon

4. General precautions
1) During long-term administration, cardiac function tests (pulse, blood pressure, electrocardiogram, X-ray, etc.) are performed regularly. In particular, if bradycardia or hypotension occurs, reduce the dose or discontinue the dose. Also, pay attention to liver function, renal function, and blood status.
2) Administration should not be stopped suddenly, and when administration is stopped, the dosage should be gradually reduced at intervals of 7 to 14 days. In the case of patients with ischemic heart disease, the medication reduction method must be observed especially carefully. There have been reports of patients with angina pectoris taking a similar compound (propranolol hydrochloride) whose symptoms worsened or myocardial infarction occurred when the medication was suddenly stopped. Therefore, if medication withdrawal is necessary, slowly reduce the dose and observe thoroughly. Be careful not to stop taking medication without doctor's instructions. In addition, when administering for applications other than angina, such as arrhythmia, caution should be taken as above, especially in elderly patients.
3) For patients planning to undergo surgery, beta-blocker treatment must be discontinued 24 hours prior to surgery. The evaluation between the risk and effectiveness of discontinuing beta-blocker medication is judged on an individual patient basis. If beta-blocker administration is continued, anesthetics with little negative inotropic activity should be used to minimize the risk of myocardial depression. Patients can be protected from vagal reactions by administering intravenous atropine.
4) Because dizziness may occur, patients taking this drug (especially in the early stages of treatment) should be careful not to operate dangerous machinery, such as driving a car.
5) Patients with atypical angina due to α-receptor-related coronary vasoconstriction should be cautious as the number or duration of angina attacks may increase.
6) Due to adverse reactions during the induction period, caution should be exercised in patients with atrioventricular block (1st degree).
7) Be careful because it may mask the symptoms of hypoglycemia, especially tachycardia.
8) β-blockers can mask the symptoms of hyperthyroidism. Therefore, if a patient with thyrotoxicosis suddenly stops taking medication, symptoms may worsen, so if a medication break is necessary, reduce the dose slowly and observe thoroughly.
9) Heart rate may be reduced due to pharmacological action. In rare cases, if symptoms improve enough to reduce heart rate, the dose may be reduced. If symptoms due to low heart rate appear in patients taking this drug or if the resting heart rate falls below at least 50 to 55 bpm, the dose should be reduced.
10) When administered to patients with a history of anaphylactic reactions to various allergens, more severe reactions may occur. These patients may not respond to typical doses of adrenaline administered to treat allergic reactions.
11) Since tenolmin is excreted through the kidneys, the dose should be reduced for patients with a creatinine clearance of less than 35mL/min/1.7m2.
12) Cardioselective (β1) blockers may have less of an effect on lung function than non-selective blockers, but all beta blockers should be prohibited from being administered to patients with reversible airway obstruction unless there is a clear clinical reason for compulsory use. Because of these reasons, the use of tenolmin also requires caution. Occasionally, increased airway resistance may occur in patients with asthma, but this can usually be treated with bronchodilators such as salbutamol or isoprenaline.

5. Interaction
1) Co-administration with other agents that suppress the sympathetic nervous system (reserpine, etc.) may cause excessive suppression, so administer with caution, such as reducing the dose.
2) The effects of β-blockers may be antagonized by co-administration with sympathomimetics such as adrenaline.
3) When used in combination with insulin or oral antidiabetic agents, the blood sugar lowering effect of these drugs may be enhanced and symptoms of hypoglycemia may occur. In particular, it can mask tachycardia symptoms.
4) When administered together with calcium antagonists (verapamil hydrochloride, diltiazem, etc.), the interaction may be enhanced. In particular, in patients with ventricular dysfunction and/or sinus atrial or atrioventricular conduction abnormalities, when β-blockers are coadministered with calcium antagonists that reduce contractility, such as verapamil or diltiazem, the effect of reducing contractility may be enhanced, which may cause severe hypotension, bradycardia, and heart failure. Other drugs (calcium antagonists or β-blockers) should not be administered intravenously within 48 hours after stopping the β-blocker or calcium antagonist.
5) When administered in combination with clonidine, the rebound phenomenon of this drug may be enhanced after stopping clonidine administration. When co-administered with clonidine, the β-blocker should be discontinued a few days before stopping clonidine. When changing from clonidine to a β-blocker, stop clonidine administration and take a break for several days (7 days) before administering the β-blocker. (Refer to clonidine prescribing information)
6) When co-administered with Class Ⅰ arrhythmia drugs such as disopyramide or quinidine, amiodarone, procainamide, or ajmaline, atrial conduction time may increase, muscle contractility may decrease, and excessive cardiac function suppression may occur, so administer with caution, such as reducing the dose.
7) Be careful when using anesthetics in patients taking this drug as it may cause excessive sympathetic depression. You must inform the anesthesiologist that you are taking this drug, and if possible, an anesthetic with less activity in reducing contractility should be selected. Concomitant use of β-blockers and anesthetics may weaken reflex tachycardia and increase the risk of hypotension. Anesthetics that can cause cardiac depression should be avoided.
8) Concurrent administration with dihydropyridine drugs (nifedipine, etc.) increases the risk of hypotension and may cause heart failure in patients with potential heart disease.
9) When digitalis preparations are used together with β-blockers, atrioventricular conduction time can be prolonged.
10) Co-administration with prostaglandin synthesis inhibitors (ibuprofen, indomethacin, etc.) may reduce the blood pressure lowering effect of β-blockers.
11) When administered together with cimetidine, the blood concentration of this drug may increase.

6. Administration to pregnant and lactating women
1) Since the safety of administration during pregnancy has not been established, it should be administered to pregnant women or women who may be pregnant only when the therapeutic benefits are judged to outweigh the risks. Beta-blockers are generally associated with decreased placental perfusion, which may lead to intrauterine death, premature delivery, and premature delivery.
2) This drug passes through the placental wall and is detected in umbilical cord blood. Clinical trials in which this drug was administered in the first trimester of pregnancy have not been conducted, and the possibility of fetal damage cannot be ruled out.
3) Since it has been reported to transfer into breast milk, avoid administration during breastfeeding and discontinue breastfeeding if unavoidable circumstances arise.
4) If a woman in labor or breastfeeding takes this medicine, there may be a risk of hypoglycemia or bradycardia in the newborn.

7. Administration to children
Safety in children has not been established.

8. Administration to elderly people
For elderly patients, pay attention to the following and administer carefully while observing the patient's condition, such as starting administration at a low dose.
1) In general, excessive lowering of blood pressure in elderly people is not desirable (cerebral infarction, etc. may occur).
2) If a medication break is necessary, reduce the dose slowly.

9. Treatment in case of overdose
Overdosage may cause bradycardia, acute heart failure, hypotension, bronchospasm, and hypoglycemia. In such cases, discontinue administration and carefully observe the patient. Gastrointestinal cleansing, activated charcoal, and laxatives are administered to inhibit drug absorption, and plasma or plasma substitutes are used to treat low blood pressure and shock. Hemodialysis or hemoperfusion may also be used.
For marked bradycardia, administer atropine sulfate 1–2 mg intravenously and, if necessary, a single intravenous dose of glucagon 10 mg. Repeat if needed or administer glucagon by intravenous infusion at 1–10 mg per hour, depending on the response. If there is no response to glucagon or glucagon is unavailable, slowly administer a beta-agonist intravenously: an initial dose of isoproterenol hydrochloride 25 micrograms, orciprenaline sulfate 0.5 mg, or dobutamine 2.5–10 micrograms/kg/min. The positive inotropic effect of dobutamine can treat hypotension and acute heart failure. In cases of overdose, these dobutamine doses may be insufficient to reverse the cardiac effects of a beta-blocker; increase the dose if necessary according to the patient’s clinical condition.
Bronchospasm can usually be treated with bronchodilators (aminophylline, isoproterenol hydrochloride, or atropine). If hypoglycemia occurs, administer glucose intravenously.

10. Precautions for storage and handling
1) Keep out of reach of children.
2) Be careful as changing it into another container may cause an accident or is undesirable in terms of maintaining quality.
3) Be careful not to store above 25℃.

5. How to save
Airtight container, stored at room temperature (1~25℃)

6. Packaging unit
30 tablets/bottle, 100 tablets/bottle

7. Expiration date
36 months from date of manufacture

Product Updates

Total 1items

No.Product NameDetailsDate of ChangeDownload
1Atenol Tab.Atenol tablets (precautions for use)2009.10.07HWPAtenol tablets (precautions for use) change (2009.10.12).hwp